KPRP

Summary

KPRP (keratinocyte proline rich protein, HGNC:31823) is a protein-coding gene on chromosome 1q21.3, encoding Keratinocyte proline-rich protein (Q5T749).

This gene encodes a proline-rich skin protein possibly involved in keratinocyte differentiation.

Source: NCBI Gene 448834 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 105 total
• MANE Select transcript: NM_001025231

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31823
Approved symbol	KPRP
Name	keratinocyte proline rich protein
Location	1q21.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000203786
Ensembl biotype	protein_coding
OMIM	613260
Entrez	448834

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000606109

RefSeq mRNA: 1 — MANE Select: NM_001025231 NM_001025231

CCDS: CCDS30862

Canonical transcript exons

ENST00000606109 — 2 exons

Exon	Start	End
ENSE00003700820	152758025	152758059
ENSE00003963215	152759561	152762056

Expression profiles

Bgee: expression breadth broad, 84 present calls, max score 96.94.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4777 / max 386.7569, expressed in 50 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5312	0.4777	50

Top tissues by expression

117 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of leg	UBERON:0001511	96.94	gold quality
zone of skin	UBERON:0000014	96.25	gold quality
skin of abdomen	UBERON:0001416	95.20	gold quality
lower esophagus mucosa	UBERON:0035834	86.20	gold quality
esophagus mucosa	UBERON:0002469	70.82	gold quality
vagina	UBERON:0000996	59.32	gold quality
esophagus	UBERON:0001043	55.99	gold quality
putamen	UBERON:0001874	53.85	gold quality
caudate nucleus	UBERON:0001873	49.43	gold quality
tonsil	UBERON:0002372	49.12	gold quality
ectocervix	UBERON:0012249	49.00	gold quality
gastrocnemius	UBERON:0001388	48.96	gold quality
nucleus accumbens	UBERON:0001882	48.76	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	48.59	gold quality
muscle of leg	UBERON:0001383	45.85	gold quality
minor salivary gland	UBERON:0001830	44.67	gold quality
heart left ventricle	UBERON:0002084	44.66	gold quality
uterine cervix	UBERON:0000002	44.60	gold quality
saliva-secreting gland	UBERON:0001044	43.55	gold quality
popliteal artery	UBERON:0002250	43.41	gold quality
tibial artery	UBERON:0007610	43.36	gold quality
multicellular organism	UBERON:0000468	42.71	gold quality
right lobe of liver	UBERON:0001114	42.70	silver quality
stromal cell of endometrium	CL:0002255	42.10	silver quality
right adrenal gland cortex	UBERON:0035827	41.89	gold quality
subcutaneous adipose tissue	UBERON:0002190	40.59	gold quality
blood	UBERON:0000178	40.49	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	40.40	gold quality
heart	UBERON:0000948	40.29	gold quality
right atrium auricular region	UBERON:0006631	40.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting KPRP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-1303	99.65	69.77	1662
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-3147	99.52	66.34	388
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-3074-5P	98.82	66.56	1414
HSA-MIR-5000-3P	98.79	65.63	1251
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-4752	98.71	68.04	833

Literature-anchored findings (GeneRIF, showing 2)

• A human gene encoding keratinocyte proline-rich protein (hKPRP), an epidermal marker expressed in stratified squamous epithelia, has a potential role in keratinocytes differentiation. (PMID:16297201)
• By allelic copy number analysis at missense single-nucleotide polymorphisms on 26 genes with copy number variation, study identified a significant association between atopic dermatitis and human KPRP. Human KPRP expression, which was localized to the upper granular layer of epidermis, was significantly decreased in atopic dermatitis compared with normal skin. (PMID:30905808)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	ttll6	ENSDARG00000054023
mus_musculus	Kprp	ENSMUSG00000059832
rattus_norvegicus	Kprp	ENSRNOG00000028865
drosophila_melanogaster	TTLL3B	FBGN0031853
drosophila_melanogaster	TTLL3A	FBGN0031854
drosophila_melanogaster	TTLL15	FBGN0037838
drosophila_melanogaster	TTLL6B	FBGN0039501
caenorhabditis_elegans		WBGENE00010630

Paralogs (12): TTLL1 (ENSG00000100271), TTLL12 (ENSG00000100304), TTLL2 (ENSG00000120440), TTLL9 (ENSG00000131044), TTLL4 (ENSG00000135912), TTLL7 (ENSG00000137941), TTLL8 (ENSG00000138892), TTLL10 (ENSG00000162571), TTLL6 (ENSG00000170703), TTLL11 (ENSG00000175764), TTLL13 (ENSG00000213471), TTLL3 (ENSG00000214021)

Protein

Protein identifiers

Keratinocyte proline-rich protein — Q5T749 (reviewed: Q5T749)

All UniProt accessions (1): Q5T749

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in the upper layer of epidermis and psoriasis (at protein level). Expressed in the upper layer of epidermis and psoriasis.

Induction. By calcium and in psoriatic lesions.

RefSeq proteins (1): NP_001020402* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR052881	Keratinocyte_PR	Family

UniProt features (10 total): sequence variant 6, chain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T749-F1	48.80	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 394

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9725554	Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
R-HSA-1266738	Developmental Biology
R-HSA-9734767	Developmental Cell Lineages

MSigDB gene sets: 37 (showing top): GOBP_EPITHELIUM_DEVELOPMENT, GOBP_INFLAMMATORY_RESPONSE, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP, DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_EPIDERMIS_DEVELOPMENT, GOBP_SKIN_DEVELOPMENT, chr1q21, GOBP_DESMOSOME_ORGANIZATION, GOBP_CELL_CELL_JUNCTION_ORGANIZATION, MIR4306, MIR4644, MIR185_5P

GO Biological Process (5): desmosome organization (GO:0002934), inflammatory response (GO:0006954), establishment of skin barrier (GO:0061436), epidermis development (GO:0008544), skin development (GO:0043588)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Developmental Cell Lineages of the Integumentary System	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell junction organization	1
defense response	1
skin epidermis development	1
tissue development	1
animal organ development	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

1680 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KPRP	SPRR4	Q96PI1	646
KPRP	LELP1	Q5T871	607
KPRP	LORICRIN	P23490	533
KPRP	CRCT1	Q9UGL9	530
KPRP	CSTPP1	Q9H6J7	527
KPRP	KPLCE	Q5T750	498
KPRP	SLC61A1	Q6N075	494
KPRP	TCHHL1	Q5QJ38	484
KPRP	S100A3	P33764	478
KPRP	MYG1	Q9HB07	475
KPRP	ZNF408	Q9H9D4	475
KPRP	CRNN	Q9UBG3	471
KPRP	PRR9	Q5T870	470
KPRP	HRNR	Q86YZ3	463
KPRP	SERPINB12	Q96P63	460

IntAct

489 interactions, top by confidence:

A	B	Type	Score
TNS2	KPRP	psi-mi:“MI:0915”(physical association)	0.700
KPRP	GLRX3	psi-mi:“MI:0915”(physical association)	0.560
KSR2	POLR3A	psi-mi:“MI:0914”(association)	0.530
ZSCAN12	A2ML1	psi-mi:“MI:0914”(association)	0.530
CCDC51	TGM5	psi-mi:“MI:0914”(association)	0.530
MMRN1	CTSV	psi-mi:“MI:0914”(association)	0.530
GPANK1	ALOX12B	psi-mi:“MI:0914”(association)	0.530
GDF5	SERPINB7	psi-mi:“MI:0914”(association)	0.530
B3GALNT1	DUSP14	psi-mi:“MI:0914”(association)	0.530
MRPL38	DUSP14	psi-mi:“MI:0914”(association)	0.530
GRB2	KPRP	psi-mi:“MI:0915”(physical association)	0.490
FHL3	KPRP	psi-mi:“MI:0915”(physical association)	0.490
Rhoa	CLK2	psi-mi:“MI:0914”(association)	0.350
YEATS4	ING3	psi-mi:“MI:0914”(association)	0.350
CDK1	RBMXL2	psi-mi:“MI:0914”(association)	0.350
COQ2	SNRPGP15	psi-mi:“MI:0914”(association)	0.350
METTL14	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
RNLS	STATH	psi-mi:“MI:0914”(association)	0.350
TOX4	A2ML1	psi-mi:“MI:0914”(association)	0.350
FCF1	SULT2B1	psi-mi:“MI:0914”(association)	0.350
ZIC1	IMPA2	psi-mi:“MI:0914”(association)	0.350
CIDEA	IGHG2	psi-mi:“MI:0914”(association)	0.350

BioGRID (335): KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Synthetic Lethality), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS), KPRP (Affinity Capture-MS)

ESM2 similar proteins: A1A580, A2A591, A2A5X4, A2A5X5, A8MUX0, A8MX34, B2RUR4, O13152, O93499, O93500, P02444, P02445, P02446, P02447, P02449, P02450, P02451, P04458, P07521, P08335, P0DV60, P20307, P20308, P25692, P60329, Q24JX8, Q24JX9, Q3LI81, Q3LI83, Q4KL71, Q5T749, Q5T750, Q5TA77, Q6PEX3, Q6R648, Q6S343, Q7TQM5, Q8IUC1, Q92012, Q98U05

Diamond homologs: B2RUR4, Q5T749, Q7TQM5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 143 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	22	13.0×	3e-16

Disease & clinical

Clinical variants and AI predictions

ClinVar

105 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	99
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

72 predictions. Top by Δscore:

Variant	Effect	Δscore
1:152759696:G:GA	donor_gain	0.4900
1:152759632:A:AG	donor_gain	0.4000
1:152759633:G:GG	donor_gain	0.4000
1:152759641:TC:T	donor_gain	0.4000
1:152759803:TG:T	donor_gain	0.3600
1:152759585:G:GT	donor_gain	0.3500
1:152759695:T:TA	donor_gain	0.3500
1:152761836:A:T	acceptor_gain	0.3500
1:152759714:G:GT	donor_gain	0.3400
1:152759911:AAAGC:A	acceptor_gain	0.3300
1:152760594:AGG:A	acceptor_gain	0.3300
1:152759636:C:G	donor_gain	0.3200
1:152759765:GTC:G	donor_gain	0.3200
1:152761871:G:C	acceptor_gain	0.3200
1:152759912:AAGC:A	acceptor_gain	0.3100
1:152760744:C:CA	acceptor_gain	0.3100
1:152759636:C:CG	donor_gain	0.3000
1:152759698:TTC:T	donor_gain	0.3000
1:152760534:A:G	acceptor_gain	0.3000
1:152760886:A:AT	acceptor_gain	0.3000
1:152760887:T:TT	acceptor_gain	0.3000
1:152759590:T:G	donor_gain	0.2900
1:152760593:CAG:C	acceptor_gain	0.2900
1:152759830:TG:T	donor_gain	0.2800
1:152760592:CCAG:C	acceptor_gain	0.2800
1:152761388:A:AG	acceptor_gain	0.2800
1:152761390:A:AG	acceptor_gain	0.2800
1:152761822:TGAA:T	acceptor_gain	0.2800
1:152761869:T:G	acceptor_gain	0.2800
1:152759749:TTC:T	donor_gain	0.2700

AlphaMissense

3732 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:152760574:T:C	I329T	0.980
1:152760483:C:A	R299S	0.973
1:152760574:T:G	I329S	0.967
1:152760628:T:C	I347T	0.935
1:152760588:T:C	C334R	0.931
1:152760481:C:A	P298H	0.925
1:152760473:C:G	C295W	0.921
1:152760499:T:A	I304K	0.917
1:152760490:C:T	S301F	0.914
1:152760574:T:A	I329N	0.914
1:152760471:T:C	C295R	0.912
1:152760568:T:A	I327N	0.912
1:152760120:T:C	F178L	0.909
1:152760122:C:A	F178L	0.909
1:152760122:C:G	F178L	0.909
1:152760483:C:G	R299G	0.906
1:152760568:T:G	I327S	0.905
1:152760564:C:G	R326G	0.900
1:152760590:C:G	C334W	0.900
1:152760496:C:A	P303H	0.897
1:152760315:T:C	F243L	0.894
1:152760317:C:A	F243L	0.894
1:152760317:C:G	F243L	0.894
1:152760565:G:C	R326P	0.893
1:152760571:A:T	E328V	0.892
1:152760480:C:A	P298T	0.887
1:152760478:C:A	P297Q	0.884
1:152760472:G:A	C295Y	0.880
1:152760628:T:G	I347S	0.880
1:152760571:A:G	E328G	0.877

dbSNP variants (sampled 300 via entrez): RS1000067276 (1:152757758 C>T), RS1000105056 (1:152758975 C>G), RS1000136427 (1:152759239 C>A,G), RS1000503889 (1:152757485 C>A), RS1002239786 (1:152761681 C>A), RS1002641671 (1:152760818 A>G), RS1002821444 (1:152756635 T>C,G), RS1003491480 (1:152756776 T>C), RS1003813025 (1:152756275 A>G), RS1004099016 (1:152761038 C>A,T), RS1004537212 (1:152758218 A>G), RS1005521252 (1:152757303 A>G), RS1005993945 (1:152758132 G>A,C), RS1006272398 (1:152758516 C>T), RS1007031910 (1:152757539 G>A,T)

Disease associations

OMIM: gene MIM:613260 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST008479_4	Psoriasis	2.000000e-08
GCST008916_82	Asthma	5.000000e-27
GCST008916_92	Asthma	6.000000e-16

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenate	decreases expression, increases abundance	1
sodium arsenite	increases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Tetrachlorodibenzodioxin	increases expression	1
Tobacco Smoke Pollution	affects expression	1
Cadmium Chloride	increases expression	1
Lactic Acid	decreases expression	1
Genistein	decreases expression, increases reaction	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer